HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%

Gregory L Price,Frank N Cinfio,Jacqueline Brown,Christopher A Bly,Pamela A Martin,Chelsea Manion,Mark E Boye,Alexandra S Vitko,Angelo Deluca

doi:10.6004/jnccn.2021.7222

HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%

Gregory L Price, Frank N Cinfio + Show 7 more

https://doi.org/10.6004/jnccn.2021.7222

Copy DOI

Journal: Journal of the National Comprehensive Cancer Network

Publication Date: Mar 31, 2022

Affiliation: Eli Lilly (United States), Medical Decision Modeling (United States)

#Node-Positive Early Breast Cancer #Abemaciclib In Combination + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

"HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%" published on 31 Mar 2022 by National Comprehensive Cancer Network.

Full Text